NEW YORK–(BUSINESS WIRE)–Schrodinger today announced receipt of a milestone payment from Ono Pharmaceutical Co., Ltd. (“Ono”) as part of a collaboration leveraging Schrodinger’s advanced computational platform to develop novel therapeutic candidates acting on the therapeutic target selected by Ono.
To advance the program, Schrodinger deployed its reaction-based enumeration tools and machine-learning technologies to identify and filter millions of potential ligands for the target that is the subject of the collaboration. Schrodinger’s physics-based computational assays were then used to predict potency with experimental accuracy. The integration of physics-based molecular simulations with machine learning enabled efficient prioritization of promising therapeutic candidates, dramatically reducing the number of compounds that had to be synthesized.
“Our collaboration with Schrodinger accelerated the drug discovery process and allowed us to advance to the target milestone very quickly,” said Toichi Takino, Ph.D., Corporate Officer and Executive Director of Discovery and Research at Ono. “We have been using Schrodinger software for years, but this collaboration takes the work to a new level, allowing us to fully leverage all the capabilities of the computational platform.”
Schrodinger has established research collaborations with leading biotech and pharmaceutical companies around the world to empower more efficient, less costly drug discovery. Such collaborations have already led to two FDA-approved oncology drugs and several clinical-stage assets. More than two dozen additional programs across multiple indications are moving through discovery and development.
“We are delighted to see this program advancing so quickly to address the enormous unmet medical need in this field,” said Karen Akinsanya, Ph.D., Schrodinger’s Chief Biomedical Scientist. “This has been a fruitful partnership as we bring together our computational resources and Ono’s insights into the disease area to serve the common goal of bringing new medicines to patients.”
Schrodinger’s industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading pharmaceutical, biotechnology, chemical, and electronics companies worldwide. In addition to this substantial and growing global business, Schrodinger has built a robust pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic. Schrodinger’s significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrodinger has nearly 400 employees in its New York City headquarters and around the world. Visit schrodinger.com for more information.
Ten Bridge Communications
Stern IR, Inc.